Diabetes: New technology opens up improved opportunities for research

More than seven million people in Germany suffer from diabetes. Drug research is still difficult. Scientists led by Peter Loskill from the NMI and the University of Tübingen have developed a technique that significantly improves the view on the molecular and cell biological level in the pancreas.

More than seven million people in Germany suffer from diabetes. At the same time, research into drugs to treat this widespread disease is still difficult. Scientists led by Prof. Dr. Peter Loskill from the NMI Natural and Medical Sciences Institute and the Faculty of Medicine of the Eberhard Karls University of Tübingen have now developed a technique that significantly improves the view at the molecular and cell biological level in the pancreas. To do this, they recreated organ-like structures on an organ-on-chip platform. Results from drug tests on these structures can be transferred to human organisms better than traditional methods. They have now published these results in the journal Lab on a Chip.

The disease diabetes (in full: diabetes mellitus) is caused by a metabolic disorder in the pancreas. The pancreas normally regulates blood sugar levels in the body by releasing the hormones insulin and glucagon.

Organ-on-chip can simulate the mode of action of real organs

Organ-on-chip technology involves growing tissue, i.e. cell clusters with specific functions, outside the body. These tissues, in this specific case made up of pancreatic cells, react to active substances in a similar way to the organ in the body. This allows reliable conclusions to be drawn about how drugs work.

Longer test durations, more informative value

“We have succeeded in reproducing a model of the insulin-producing units of the pancreas in microfluidic chips. We were also able to integrate tiny sensors into this chip that allow us to make statements about the condition of the organ model in real time without affecting the cells,” explains Peter Loskill, Professor of Organ-on-Chip Systems. “Microfluidic” means that nutrients are transported to the cells via very fine channels, just like through blood vessels, and metabolic products are removed. “By recreating the cells’ natural microenvironment in the body, we can carry out significantly longer and more meaningful experiments.” The development therefore offers the opportunity to make great progress, and not just in diabetes research.

How does Organ-on-Chip work?

For organ-on-chip models, organ-specific cells are grown outside the body in a customized microenvironment in a microfluidic chip. The cells can correspond to those of the pancreas, liver, heart muscle or brain, for example. The tissues built up from the cells are continuously supplied with nutrients on the chip in a similar way to the bloodstream. This allows them to be treated with medication, for example, or a disease state can be simulated through targeted manipulation. Using a variety of analysis methods, it is possible to carry out time-resolved measurements of reactions to active substances or the progression of diseases. Due to the possibility of working with human cells in particular, studies on organs-on-chips are potentially more transferable to humans than animal experiments, which could lead to a significant reduction in animal experiments in basic biomedical research and pharmaceutical research in the future.

Paper:

Microphysiological pancreas-on-chip platform with integrated sensors to model endocrine function and metabolism – Lab on a Chip (RSC Publishing)

About the NMI:

The NMI Natural and Medical Sciences Institute in Reutlingen is a non-university research institution and conducts application-oriented research at the interface of biosciences and materials science. It has a unique, interdisciplinary range of expertise for R&D and services for regional and international companies. The institute addresses the healthcare industry as well as companies from the automotive, mechanical engineering and toolmaking sectors. At the same time, the NMI actively supports spin-offs from the institute.

In research, the NMI cooperates with numerous top-class institutions such as the University of Tübingen, the University Hospital Tübingen and the institutes of the innBW network.

The NMI is supported by the Baden-Württemberg Ministry of Economics, Labor and Tourism and is a member of the Baden-Württemberg Innovation Alliance, an association of 12 non-university and business-related research institutes.

https://www.nmi.de/en/
http://www.linkedin.com/company/natural-and-medical-sciences-institute-at-univer…

About the 3R-Center Tübingen:

The 3R Center Tübingen for In Vitro Models and Animal Alternatives is actively involved in the three areas of “Education, Training & Consulting”, “Research” and “Science Communication & Public Relations” to promote state-of-the-art replacement and complementary methods to animal experiments and to advance their consistent application. It supports (young) scientists in (bio)medical research and representatives of the pharmaceutical industry in integrating human microphysiological systems, such as organ-on-chip and organoid models, into their processes and thus reducing the number of unavoidable animal experiments to a minimum. At the same time, the 3R Center advises political decision-makers. As part of the 3R Network Baden-Württemberg, the 3R Center Tübingen has been jointly supported by the Faculty of Medicine of the Eberhard Karls University of Tübingen and the NMI Natural and Medical Sciences Institute in Reutlingen since its foundation in 2020.

https://www.the3rs.uni-tuebingen.de/en/3r-center-tuebingen
https://twitter.com/3RCenter
https://www.linkedin.com/company/3rtuebingen/

Originalpublikation:

https://pubs.rsc.org/en/content/articlelanding/2024/lc/d3lc00838j